SSC-SYSTEMIC SCLEROSIS
Clinical trials for SSC-SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new SSC-SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for SSC-SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cell therapy targets Hard-to-Treat scleroderma
Disease control Recruiting nowThis early-phase study tests a new treatment called CT1195E CAR-T cells for people with severe systemic sclerosis (scleroderma) that hasn't responded to other therapies. The therapy uses a patient's own immune cells, modified to attack disease-causing cells. The study aims to fin…
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage study is testing a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that drive autoimmune diseases like lupus and scleroderma. The therapy is given as a one-time infusion and aims to reset …
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug CC312 tested for tough autoimmune cases
Disease control Recruiting nowThis early study is testing the safety of a new drug, CC312, in 6 adults with lupus, myositis, or systemic sclerosis that has come back or not responded to standard treatments. Participants receive increasing doses of CC312 by IV to see if it is safe and tolerable. The goal is to…
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Can a triple therapy slow lung damage in scleroderma?
Disease control Recruiting nowThis study looks at whether adding an anti-fibrotic drug to two immunosuppressants can better protect lung function in people with scleroderma-related interstitial lung disease. About 35 adults will be followed for a year with regular breathing tests. The goal is to see if the ex…
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Sponsor: University of Patras • Aim: Disease control
Last updated May 05, 2026 11:53 UTC